Skip to main content
. 2022 Mar 17;6:16. doi: 10.1038/s41698-022-00260-0

Fig. 5. Drug sensitivity profile of ALK-positive cancer cell lines and PDCs using focused inhibitor library screening.

Fig. 5

Cell viability of ALK-positive cancer cell lines and PDCs treated with each inhibitor with or without 300 nM lorlatinib for 72 h was measured (n = 2). Relative cell viability was calculated from each value divided by the DMSO control.